GLAXO MOVES TO PROTECT FORM 1 ZANTAC PATENT
Executive Summary
GLAXO MOVES TO PROTECT FORM 1 ZANTAC PATENT, which is being challenged by the Canadian generic drug company Genpharm. Glaxo announced Dec. 30 that it had instituted its second round of U.S. legal proceedings against Genpharm with the filing of a law suit in Baltimore federal court that seeks to protect Glaxo's basic patent (U.S. Patent 4,128,658) for its Form 1 Zantac (ranitidine HCl). That patent expires in December 1995.